Open AccessDevil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
Author(s) -
Matthew R. Strickland,
Pasi A. Jänne
Publication year - 2020
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm-20-4253
Subject(s) - exon , splice , mutation , surrogate endpoint , genetics , rna splicing , cancer research , medicine , computational biology , biology , gene , rna
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Correspondence to: Pasi A. Jänne, MD, PhD. Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue; LC4114, Boston, MA 02215, USA. Email: Pasi_Janne@dfci.harvard.edu. Comment on: Baldacci S, Figeac M, Antoine M, et al. High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. J Thorac Oncol 2020;15:120-4.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom